Information Provided By:
Fly News Breaks for November 1, 2019
AMED
Nov 1, 2019 | 09:04 EDT
As reported previously, Baird analyst Matthew Gillmor upgraded Amedisys to Outperform from Neutral. The analyst said the CMS ruling for Home Health Payments was much better while the behavioral adjustment was moderated and improves the Medicare rate outlook in 2020. The upgrade reflects higher estimates and confidence share can sustain a higher multiple. Gillmor raised his price target to $160 from $140 on Amedisys shares.
News For AMED From the Last 2 Days
There are no results for your query AMED